uu.seUppsala universitets publikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumoursthe MACBETH project
ASST Monza, Phase 1 Trials Res Unit, Monza, MB, Italy; ASST Monza, Oncol Unit, Monza, MB, Italy; Milano Bicocca Sch Med, Monza, MB, Italy.
Ctr Integral Oncol Clara Campal HM CIOCC, Unidad Canc Mama, Madrid, Spain.
Regina Elena Inst Canc Res, Med Oncol, Rome, Italy.
Hosp Clin San Carlos, ISCIII, IdISSC CIBERONC, Dept Med Oncol, Madrid, Spain.
Visa övriga samt affilieringar
2019 (Engelska)Ingår i: Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, E-ISSN 1432-0843, Vol. 83, nr 2, s. 301-318Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Introduction: Despite the large use of nab-paclitaxel as a treatment option in metastatic breast cancer (MBC) across different countries, no definitive data are available in particular clinical situations.

Areas covered: Efficacy, safety and schedule issues concerning available literature on nab-paclitaxel in advanced breast cancer and in specific subgroups of patients have been discussed and voted during an International Expert Meeting. Ten expert specialists in oncology, with extensive clinical experience on Nab-P and publications in the field of MBC have been identified. Six scientific areas of interest have been covered, generating 13 specific Statements for Nab-P, after literature review. For efficacy issues, a summary of research quality was performed adopting the GRADE algorithm for evidence scoring. The panel members were invited to express their opinion on the statements, in case of disagreement all the controversial opinions and the relative motivations have been made public.

Expert opinion: Consensus was reached in 30.8% of the Nab-P statements, mainly those regarding safety issues, whereas ones regarding efficacy and schedule still remain controversial areas, requiring further data originated by the literature.

Ort, förlag, år, upplaga, sidor
2019. Vol. 83, nr 2, s. 301-318
Nyckelord [en]
Expert meeting, Nab-paclitaxel, Breast cancer, Weekly schedule, Neuropathy
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
URN: urn:nbn:se:uu:diva-378731DOI: 10.1007/s00280-018-3717-2ISI: 000459155300007PubMedID: 30460489OAI: oai:DiVA.org:uu-378731DiVA, id: diva2:1294885
Tillgänglig från: 2019-03-08 Skapad: 2019-03-08 Senast uppdaterad: 2019-03-08Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed

Personposter BETA

Lindman, Henrik

Sök vidare i DiVA

Av författaren/redaktören
Lindman, Henrik
Av organisationen
Experimentell och klinisk onkologi
I samma tidskrift
Cancer Chemotherapy and Pharmacology
Cancer och onkologi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 12 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf